Suzetrigine: A New Non-Opioid Analgesic Option With Potential Implications for Serious Illness Care
{{output}}
In this letter, the authors evaluate the potential of suzetrigine, a newly U.S. Food and Drug Administration-approved selective NaV1.8 sodium channel inhibitor, as a novel nonopioid alternative for managing moderate-to-severe pain. By targeting peripheral sens... ...
